Adding losartan to improve Trikafta response in CF
Treatments studied
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests whether adding the blood pressure medication losartan can help the standard CF drug Trikafta work better by reducing inflammation. It's for people with CF who still have high sweat chloride levels despite taking Trikafta.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of cystic fibrosis (CF) and are 12 years or older.
- You have been taking Trikafta (elexacaftor/tezacaftor/ivacaftor) for at least 90 days.
- Even with Trikafta, your sweat chloride level is still 50 mmol/L or higher.
- You have not had a lung transplant.
- Your body mass index (BMI) is 18 or higher.
- You have not had a CF flare-up needing hospital care or IV antibiotics in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding metformin can improve blood-sugar control and related lung cell function in adults who have cystic-fibrosis–related diabetes (CFRD) and are already taking CFTR modulator therapy. It may help if your diabetes is still not well controlled despite those CF medicines.
This study tests how starting Trikafta affects exercise ability and breathing in adults with cystic fibrosis. You may be asked to do supervised breathing and exercise tests to see if Trikafta helps your lung function and stamina.
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.